Seres Therapeutics Set for Breakout on Impending Clinical Results
AI Prediction of Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, with its innovative microbiome therapeutic platform, presents a compelling investment opportunity, especially with upcoming clinical trial results expected to be a major catalyst. The company's focus on treating dysbiosis in the colonic microbiome could potentially redefine treatment paradigms across several gastrointestinal disorders.
MCRB Report Information
Prediction Date2025-07-03
Close @ Prediction$11.87
Mkt Cap72m
IPO DateN/a
AI-derived Information
Recent News for MCRB
- May 12, 7:00 am — Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference (GlobeNewswire RSS)
- May 5, 7:14 am — Seres Therapeutics: Q1 Earnings Snapshot (Associated Press)
- May 5, 7:00 am — Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
- May 4, 7:00 am — Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease (GlobeNewswire)
- Apr 20, 7:00 am — Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 (GlobeNewswire)
- Apr 9, 7:00 am — Seres Therapeutics to Present at CARB-X Investor Day (GlobeNewswire)
- Mar 12, 7:23 am — Seres Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
- Mar 12, 7:00 am — Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
- Mar 2, 4:05 pm — Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates (GlobeNewswire)
- Feb 12, 8:29 am — Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash (Benzinga)
- Feb 12, 7:00 am — Seres to lay off staff, pause top program in latest reboot (BioPharma Dive)
- Feb 12, 7:00 am — Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases (GlobeNewswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.